Seaport Therapeutics, Inc. IPO - What You Need to Know

Thinking about the Seaport Therapeutics IPO? Getting in early on a biotech company is exciting, but these investments can be a rollercoaster. Here is a plain-English breakdown of what you need to know before you decide to buy.

1. What does this company do?

Seaport specializes in drug delivery, specifically for brain-related conditions like depression and anxiety. Many current brain drugs cause side effects like nausea or sedation because they travel through the whole body and the liver before reaching their target.

Seaport uses a platform called "Glyph." Think of it as a "stealth delivery truck." They attach a drug to a natural fat molecule, which allows the medicine to bypass the liver and enter the lymphatic system directly. This approach may allow for lower doses and fewer side effects.

2. What is in their pipeline?

They have three main projects currently in development:

• SPT-300: A treatment for Major Depressive Disorder. They are running a trial with about 360 patients and expect results in early 2027.
• SPT-320: A treatment for Generalized Anxiety Disorder. They use the Glyph platform to help the body absorb the drug more effectively.
• SPT-348: A treatment for depression and PTSD. It aims to provide benefits without the hallucinogenic effects often associated with other experimental drugs in this space.

3. How do they make money?

Currently, they don’t. Like many early-stage biotech firms, they are still in the research phase. They have no product sales and have lost money since they started. They are burning through cash to fund clinical trials and research.

They expect their current cash, plus the money from this IPO, to fund operations until 2029. However, this is just an estimate. If trials take longer or cost more than expected, they will run out of money sooner.

4. What are the main risks?

• The "All or Nothing" Risk: Their success depends entirely on their clinical trials. If their drugs fail to prove safe or effective, the stock price could drop significantly.
• The Need for More Cash: They will eventually need more money to finish development. They may issue more shares, which reduces your ownership percentage, or take on debt.
• Regulatory Hurdles: The FDA must approve their drugs. This process is long, expensive, and unpredictable. There is no guarantee they will get approval.
• Dependency: They rely on a license from Monash University for their core technology. If they lose this license or the patents are challenged, their business model could be severely impacted.

5. The IPO Details

• Ticker Symbol: "SPTX" on the Nasdaq.
• Price Range: Expected between $16.00 and $18.00 per share.
• The Offering: They are selling 11.8 million shares to the public.

6. Who is running the show?

The leadership team has a strong track record. The founders helped build Karuna Therapeutics, which was sold for $14 billion. While past success does not guarantee future results, their experience navigating the complex FDA approval process is a significant asset for a company at this stage.

Final Advice for Investors: Investing in a company with no revenue is inherently high-risk. Because Seaport is years away from potentially selling a product, this is a "long game" investment. Only invest money you can afford to lose, and keep this as a small, speculative part of a diversified portfolio.

Disclaimer: I am an AI, not a financial advisor. This guide is for information only and is not financial advice. Always do your own research or consult with a professional before making investment decisions.